Interview: Interview with Brad Gray for Personalized Medicine.
On 29 June 2010 Brad Gray became the President and Chief Executive Officer of the privately held life sciences company NanoString Technologies, WA, USA. Previously the Vice President of Product and Business Development at Genzyme Genetics, the diagnostic services division of Genzyme Corporation, Brad was in charge of developing molecular diagnostics and partnering activities. In December 2010, NanoString announced its securing of an exclusive worldwide license to develop in vitro diagnostic and research products for breast cancer intrinsic subtyping with the PAM50 gene signature. Brad Gray received a BA in Economics and Management from Oxford University, where he studied as a British Marshall Scholar, and an SB in Chemical Engineering from the Massachusetts Institute of Technology. Brad was also a management consultant in the healthcare practice of McKinsey & Company.